Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Mandarin Capital Pays $17 Million for Majority Stake in Italian CMO

publication date: Dec 8, 2016
Mandarin Capital Partners, a China private equity firm, paid $17.4 million to acquire a majority stake in an Italian CMO, Mipharm SpA of Milan. Mipharm specializes in making generic drugs and has traditionally had a close relationship with Sandoz, the generic arm of Novartis. Mandarin Capital focuses on European companies and on European businesses that want to expand into China. It closed its second fund, Mandarin Capital Partners II, early this year at $218 million. More details....

Stock Symbol: (NYSE NVS)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital